Elevated serum levels of IGF-1 are sufficient to establish normal body size and skeletal properties even in the absence of tissue IGF-1

Journal of Bone and Mineral Research

Volumn 25, Issue 6, 2010, Pages 1257-1266

  Elis, Sebastien ^a   Courtland, Hayden William ^a   Wu, Yingjie ^a   Rosen, Clifford J ^b   Sun, Hui ^a   Jepsen, Karl J ^a   Majeska, Robert J ^c   Yakar, Shoshana ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Maine Medical Center Research Institute   (United States)

^c City University of New York   (United States)

Author keywords

Bone; Endocrine IGF 1; IGF 1; IGF 1KO; Mechanical properties; Micro computed tomography; Transgenic mice

Indexed keywords

SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BODY HEIGHT; BODY SIZE; BODY WEIGHT; BONE DEVELOPMENT; BONE STRUCTURE; CONTROLLED STUDY; FEMALE; LIVER; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; POSTNATAL GROWTH; PROTEIN EXPRESSION;

ANIMALS; ANIMALS, NEWBORN; AUTOCRINE COMMUNICATION; BIOMECHANICS; BODY SIZE; BONE AND BONES; CELL COUNT; GENE EXPRESSION REGULATION; INSULIN-LIKE GROWTH FACTOR I; MICE; MODELS, BIOLOGICAL; OSTEOBLASTS; OSTEOCLASTS; PARACRINE COMMUNICATION; PERIOSTEUM; SEXUAL MATURATION;

EID: 77953481694     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.20     Document Type: Article

References (34)

1. Silha JV, Murphy LJ. Insulin-like growth factor binding proteins in development. Adv Exp Med Biol. 2005;567:55-89. (Pubitemid 43759190)
2. Daughaday WH. Growth hormone axis overview: somatomedin hypothesis. Pediatr Nephrol. 2000;14:537-40.
3. Isaksson O, Ohlsson C, Sjogren K, Wallenius K, Jansson JO. The somatomedin hypothesis revisited in a transgenic model. Growth Horm IGF Res. 2001;11(Suppl A):S49-52.
4. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev. 2001;22:53-74.
5. Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol. 2001;229:141-62.
6. Mohan S, Richman C, Guo R, et al. Insulin-like growth factor regulates peak bone mineral density in mice by both growth hormone-dependent and -independent mechanisms. Endocrinology. 2003;144:929-36.
7. Efstratiadis A. Genetics of mouse growth. Int J Dev Biol. 1998;42:955-76.
8. Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993;75:73-82. (Pubitemid 23306022)
9. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell. 1993;75:59-72. (Pubitemid 23306021)
10. Yakar S, Canalis E, Sun H, et al. Serum IGF-1 Determines Skeletal Strength by Regulating Sub-Periosteal Expansion and Trait Interactions. J Bone Miner Res. 2009.
11. Backeljauw PF, Underwood LE. Therapy for 6. 5-7. 5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study. J Clin Endocrinol Metab. 2001;86:1504-10.
12. Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab. 2007;92:902-10. (Pubitemid 46465661)
13. Guevara-Aguirre J, Rosenbloom AL, Vasconez O, et al. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency. J Clin Endocrinol Metab. 1997;82:629-33. (Pubitemid 27068641)
14. Klinger B, Laron Z. Three year IGF-I treatment of children with Laron syndrome. J Pediatr Endocrinol Metab. 1995;8:149-58.
15. Ranke MB, Savage MO, Chatelain PG, et al. Insulin-like growth factor I improves height in growth hormone insensitivity: two years' results. Horm Res. 1995;44:253-64.
16. Sims NA, Clement-Lacroix P, Da Ponte F, et al. Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5. J Clin Invest. 2000;106:1095-103.
17. Wu Y, Sun H, Yakar S, Leroith D. Elevated levels of IGF-1 in serum rescue the severe growth retardation of IGF-1 null mice. Endocrinology. 2009.
18. Yakar S, Bouxsein ML, Canalis E, et al. The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone. J Endocrinol. 2006;189:289-99. (Pubitemid 43757787)
19. Yakar S, Rosen CJ, Beamer WG, et al. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest. 2002;110:771-81.
20. Yakar S, Setser J, Zhao H, et al. Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest. 2004;113:96-105. (Pubitemid 38541636)
21. Jepsen KJ, Hu B, Tommasini SM, et al. Genetic randomization reveals functional relationships among morphologic and tissue-quality traits that contribute to bone strength and fragility. Mamm Genome. 2007;18:492-507. (Pubitemid 47360414)
22. Barron M, McAllister D, Smith SM, Lough J. Expression of retinol binding protein and transthyretin during early embryogenesis. Dev Dyn. 1998;212:413-22. (Pubitemid 28294870)
23. Makover A, Soprano DR, Wyatt ML, Goodman DS. An in situ-hybridization study of the localization of retinol-binding protein and transthyretin messenger RNAs during fetal development in the rat. Differentiation. 1989;40:17-25. (Pubitemid 19149289)
24. Soprano DR, Soprano KJ, Wyatt ML, Goodman DS. Induction of the expression of retinol-binding protein and transthyretin in F9 embryonal carcinoma cells differentiated to embryoid bodies. J Biol Chem. 1988;263:17897-900.
25. Steinhelper ME, Cochrane KL, Field LJ. Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. Hypertension. 1990;16:301-7.
26. Juul A, Dalgaard P, Blum WF, et al. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab. 1995;80:2534-42.
27. Sabatier JP, Guaydier-Souquieres G, Laroche D, et al. Bone mineral acquisition during adolescence and early adulthood: a study in 574 healthy females. 10-24. years of age. Osteoporos Int. 1996;6:141-8.
28. Bailey DA, McKay HA, Mirwald RL, Crocker PR, Faulkner RA. A six-year longitudinal study of the relationship of physical activity to bone mineral accrual in growing children: the university of Saskatchewan bone mineral accrual study. J Bone Miner Res. 1999;14:1672-9.
29. Stratikopoulos E, Szabolcs M, Dragatsis I, Klinakis A, Efstratiadis A. The hormonal action of IGF1 in postnatal mouse growth. Proc Natl Acad Sci U S A. 2008;105:19378-83.
30. Tommasini SM, Hu B, Nadeau JH, Jepsen KJ. Phenotypic integration among trabecular and cortical bone traits establishesmechanical functionality of inbredmouse vertebrae. J Bone Miner Res. 2009;24:606-20.
31. Jiang J, Lichtler AC, Gronowicz GA, et al. Transgenic mice with osteoblast-targeted insulin-like growth factor-I show increased bone remodeling. Bone. 2006;39:494-504. (Pubitemid 44149270)
32. Zhang M, Xuan S, Bouxsein ML, et al. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem. 2002;277:44005-12. (Pubitemid 36157826)
33. Zhao G, Monier-Faugere MC, Langub MC, et al. Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology. 2000;141:2674-82. (Pubitemid 32269089)
34. Backeljauw PF, Underwood LE. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome - a clinical research center study. GHIS Collaborative Group. J Clin Endocrinol Metab. 1996;81:3312-7.